Global Forum council appoints new executive director
This article was originally published in Scrip
Executive Summary
The Foundation Council of the Global Forum for Health Research, an independent organisation focused on the role of research and innovation in health and health equity for poor and marginalised populations, has appointed Professor Anthony Mbewuexecutive director, effective January 2010. Professor Mbewu is president of the Medical Research Council of South Africa, vice-chair of the board of the TB Alliance and a member of the strategy working group for the US National Institute for Allergy and Infectious Diseases. He succeeds Professor Stephen Matlin, who has served in the role since 2004 and will retire at the end of year.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).